How to Deal with the Projected Rise of Prostate Cancer Cases in the Chinese Healthcare System

(UroToday.com) A session on the global reach of advanced prostate cancer in low- and lower-middle-income countries and a presentation by Dr. Dingwei Ye on how to tackle it at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) meeting Was discussed. Prostate cancer cases are projected to increase in the Chinese healthcare system. Prostate cancer cases are increasing in China, now 6th Most common male cancers, 18.61 cases per 100,000 men in 2022:

Additionally, the volume of radical prostatectomies at Dr. Ye’s institution, Fudan University Shanghai Cancer Center, has increased dramatically over the past decade:


Whether or not prostate cancer cases have increased in China, there is an imbalance in diagnosis, with the majority of cases being diagnosed in urban areas compared to rural areas:


Dr. Ye also emphasized that prostate cancer ranks 7thth Cancer mortality and 5-year survival rates among men in China are much lower than in other countries:


Of note, there are epidemiological differences in prostate cancer between China and the United States, with prostate cancer patients in China being diagnosed at a later stage.

Dr. Ye emphasized that one way to deal with the increase in cases in China is the Healthy China Initiative (2019-2030), which was announced by the State Council and is designed to reduce potential life years, improve cancer survival, Designed to improve survival outcomes. And early diagnosis rates will improve. Dr. Yeh says there are cancer screening policies in place for breast, upper gastrointestinal, colorectal, liver and lung cancers, but there is a lack of a screening policy for prostate cancer. As such, local agencies are developing their own screening strategies in the eastern coastal areas. There is also an emphasis on upgrading medical facilities to improve hospitals and equipment to meet the treatment needs of more patients. Additionally, there is a need for resource integration to optimize medical processes, improve treatment efficiency, and reduce patient economic burden. At present, there are 314 da Vinci surgical robotic sets in China, which have the following distribution in the country, which is definitely in favor of the former:


Current models of robots include Ronovo, Jingheng and Toumai:


Expediting drug approvals is an important initiative. The following examples of enzalutamide and olaparib illustrate the substantial differences between approvals in the United States and China:


Dr. Ye also noted that China is also working on multidisciplinary collaboration specifically for prostate cancer:


In fact, hospital tumor boards began in China in 2005, followed by domestic tumor boards in 2015, and now international tumor boards in 2018:


Dr. Ye concluded his presentation by discussing how to deal with the projected increase of prostate cancer cases in the Chinese health care system with the following take-home messages:

Presenter: Dingwei Ye, Fudan University Shanghai Cancer Center, Shanghai, China

Author: Zachary Klaassen, MD, MSc – Urologic Oncologist, Associate Professor of Urology, Georgia Cancer Center, WellStar MCG Health, on Twitter @zklaassen_md 2024 Advanced Prostate Cancer Consensus Conference (APCCC) Meeting, Lugano, Switzerland, Thursday, April 25 – Saturday, April 27, 2024.